Huttig Building Products, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jon Vrabely
- Full Time Employees
- 1,100
- Sector
- Consumer Cyclical
- Industry
- Home Improvement
- Address
- 555 Maryville University Dr Ste 400 St. Louis MO United States of America 63141
- IPO Date
- Dec 8, 1999
- CIK
- 0001093082
- Website
- huttig.com
- Similar Companies
- Business
- Huttig Building Products, Inc. is a leading distributor of millwork, building materials, and wood products primarily serving new residential construction, in-home improvement, remodeling, and repair markets in the United States. The company offers an extensive range of products including exterior and interior doors, pre-hung and factory-finished door units, windows, patio doors, mouldings, frames, stair parts, columns, decking, siding, trim, fasteners, house wrap, and other specialty building products. Huttig distributes brands such as Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door, providing value-added services like pre-hanging and pre-finishing door systems and customized finishing solutions. Founded in 1886 and headquartered in St. Louis, Missouri, Huttig has historically operated as one of the largest wholesale distributors in its sector, focusing on commercial and residential construction and remodeling through a broad network of distribution centers. The company maintains a loyalty program, online configurators, and other customer service innovations to support dealer success. In a major strategic development, Huttig Building Products was acquired by Woodgrain Inc., a millwork manufacturer, in an all-cash transaction finalized in 2022 for approximately $350 million. Post-acquisition, Huttig's operations have been fully integrated into Woodgrain's distribution division under the Woodgrain brand name, expanding Woodgrain’s footprint with an extended distribution center network and enhanced product and service offerings. The acquisition allows Woodgrain to leverage Huttig’s resources, expertise, and established customer relationships to provide a broader assortment of specialty building materials and value-added services across key U.S. markets, including the Northeast, Midwest, South, and West. This merger has involved standardizing business processes, investing in facility upgrades, and integrating teams to drive growth and customer value. Huttig's portfolio now benefits from Woodgrain’s vertical integration capabilities and manufacturing expertise, underpinning an expanded range of building materials logistics, fasteners, connectors, and wood products with nationwide reach. The business supports 3PL and reload programs, transportation networks, and material handling services, positioning the combined entity as a premier supplier and service provider in the building materials distribution industry. Overall, Huttig Building Products operates as a vital division of Woodgrain Inc., offering a comprehensive and trusted suite of specialty building products and millwork backed by extensive distribution infrastructure and enhanced value-added capabilities across the U.S. building and remodeling market.
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
Helix BioPharma (TSE:HBP) Stock Passes Above Fifty Day Moving Average – Should You Sell?
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Helix BioPharma (TSE:HBP) Stock Passes Below Fifty Day Moving Average – Time to Sell?
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Helix BioPharma Responds to Market Activity
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting
Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group
Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.
Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan
Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025